1.Evaluating the specific STAT3 inhibitor YHO-1701 in ovarian cancer cell lines and patient-derived cell models: efficacy, mechanisms, and therapeutic potential
Sho SATO ; Takahito MIURA ; Aiko OGASAWARA ; Daisuke SHINTANI ; Shogo YAMAGUCHI ; Hiroaki INUI ; Akiko YOSHINAGA ; Masahiko NISHIYAMA ; Momomi TSUGANE ; Kosei HASEGAWA
Journal of Gynecologic Oncology 2025;36(2):e24-
Objective:
Signal transducer and activator of transcription 3 (STAT3) plays key roles in regulating cancer cell proliferation, survival, and metastasis. We aimed to determine the effects of YHO-1701, an oral STAT3 inhibitor, in ovarian cancer (OC).
Methods:
We evaluated the impact of YHO-1701 on cell growth in patient-derived cells (PDCs) and OC cell lines using standard cell proliferation assays. Spheroid models derived from PDCs were assessed using three-dimensional (3D) cell viability assays. Antitumor activity was performed in SKOV3 xenograft mice treated orally administrated YHO-1701 with 20 mg/kg.Changes in STAT3 signaling were analyzed by western blotting. The molecular mechanisms of STAT3 inhibition were investigated by sequencing RNA and analyzing pathways in the SKOV3 using a small interfering RNA targeting STAT3 (STAT3 siRNA) and YHO-1701.
Results:
YHO-1701 inhibited the growth of OC cell lines by preventing STAT3 dimerization and decreasing the expression of its downstream signaling molecule, survivin. The growth of PDCs and spheroids obtained from patients with primary and recurrent OCs was significantly inhibited. Antitumor effect was observed in the SKOV3 xenograft mice with YHO-1701. YHO-1701 induced apoptosis in OC cells. Additionally, p53 and/or MAPK signaling pathways were upregulated in SKOV3 cells incubated with YHO-1701 and in those with STAT3 siRNA.
Conclusion
Our results showed that YHO-1701 suppressed cell growth in PDCs of OC, accompanied by survivin inhibition, and a decrease in the number of peritoneal metastasis in the mice by YHO-1701, compared with those treated with control. Therefore, YHO-1701 could be a promising candidate agent for treating OC
2.Hybrid Aortic Repair for Visceral Aortic Patch Aneurysm after Thoracoabdominal Aortic Aneurysm Repair
Ryuki YAMADA ; Hideki UEDA ; Hiroki KONO ; Kaoru MATSUURA ; Michiko WATANABE ; Tomohiko INUI ; Yasunori YAKITA ; Yusuke SHIBATA ; Hiroaki YAMAMOTO ; Goro MATSUMIYA
Japanese Journal of Cardiovascular Surgery 2020;49(6):385-389
We report a 48-year-old man who underwent hybrid aortic repair for visceral aortic patch (VAP) aneurysm. He had undergone descending thoracic aortic repair for post-dissection aneurysm at the age of 25, ascending aorta and proximal aortic arch aneurysm repair at the age of 27, and residual thoracoabdominal dissecting aortic aneurysm repair with VAP reconstruction at the age of 28. During 20 years of follow-up, the VAP gradually enlarged and eventually reached 70×61 mm in diameter. Considering a possible severe adhesion after 2 previous left thoracotomies, we planned a 2-staged hybrid aortic repair. First, we performed reno-visceral debranching and as a second stage operation, endovascular aortic repair was performed successfully 39 days after the first-stage operation.
3.Footballer's ankle: a case report.
Yaonan ZHANG ; Hashimoto JUN ; Inui HIROAKI ; Nobuhara KATSUYA
Chinese Medical Journal 2002;115(6):942-943
Footballer 's ankle is anterior bony spur or anterior impingement symptom of the ankle with anterior ankle pain, limited and painful dorsiflexion. The cause is commonly seen in athletes and dancers, and is probably due to repetitive minor trauma. The condition was firstly described by Morris; McMurray reported good results from excision of the spurs, naming it footballer' s ankle. Opening resection of osteophytes of the anterior tibial and superior talar is an effective treatment for anterior impingement of the ankle.
Adult
;
Ankle Injuries
;
etiology
;
Athletic Injuries
;
etiology
;
Football
;
Humans
;
Male


Result Analysis
Print
Save
E-mail